BioMarin Pharmaceutical Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B |
| Cost of Revenue | $717.4M | $580.2M | $532.1M | $503.0M | $470.5M | $524.3M | $359.5M | $315.3M |
| Gross Profit | $2.50B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B |
| Gross Margin | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% |
| Operating Expenses | ||||||||
| Research & Development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M | $628.1M | $715.0M | $696.3M |
| SG&A Expense | $1.15B | $1.01B | $892.4M | $823.2M | $759.4M | $737.7M | $680.9M | $604.4M |
| Operating Income | $409.5M | $484.2M | $185.8M | $161.0M | $-82.3M | $-43.4M | $-100.5M | $-123.5M |
| Operating Margin | 12.7% | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% |
| Interest Expense | — | — | $17.3M | $16.0M | $15.3M | $29.3M | $23.5M | $43.7M |
| Pretax Income | $482.5M | $541.8M | $188.6M | $149.6M | $-75.4M | $-49.0M | $-94.8M | $-142.7M |
| Income Tax Expense | $133.6M | $114.9M | $20.9M | $8.0M | $-11.3M | $-903.0M | $-71.0M | $-65.5M |
| Net Income | $348.9M | $426.9M | $167.6M | $141.6M | $-64.1M | $854.0M | $-23.8M | $-77.2M |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 |
| Shares Outstanding (Basic) | 191.8M | 190.0M | 187.8M | 185.3M | 182.9M | 180.8M | 179.0M | 177.1M |
| Shares Outstanding (Diluted) | 197.4M | 196.7M | 191.6M | 189.0M | 182.9M | 191.7M | 179.0M | 177.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |